# A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07169994/  
OnCo record `nct07169994` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of YL202, Toripalimab in non-small-cell lung cancer and small-cell lung cancer, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07169994 by MediLink Therapeutics (Suzhou) Co., Ltd., with 414 participants planned, started 2025-09-02 and due to reach its primary completion in 2026-09-01. Interventions recorded: YL202 for injection; Toripalimab injection, YL202 for injection; Furmonertinib Mesilate Tablets. Conditions listed: Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07169994
- Phase: 1/2
- Setting: A Multi-center, Open-Label, Phase Ib/II Study of YL202 in Combination With Anti-tumor Therapy to Evaluate the Safety, Tolerability, and Efficacy in Patients With Advanced Solid Tumors
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 414

## Sources

- ClinicalTrials.gov NCT07169994: https://clinicaltrials.gov/study/NCT07169994

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/), [YL202](https://onco.cc/drugs/yl202/)
- companies: [MediLink Therapeutics](https://onco.cc/companies/medilink/)

---
JSON: https://onco.cc/api/v1/entities/nct07169994.json